News

Latest valve and structural heart intelligence

28 articles tagged Guidelines
CVB
news·11 days ago·Cardiovascular Business

Cardiologist explains why TAVR may be beneficial for select patients with moderate aortic stenosis

A cardiologist discusses the potential role of TAVR in treating select patients with moderate aortic stenosis, an indication that extends beyond current approved severe AS populations. The article explores clinical rationale for expanding TAVR use to patients with less advanced valvular disease.

Digest: Expansion of TAVR to moderate AS represents a significant potential market growth opportunity and would fundamentally shift treatment paradigms for earlier-stage aortic valve disease.

TAVRGuidelinesMarketRead original
CVB
research·20 days ago·Cardiovascular Business

Degenerative mitral valve disease: Key takeaways from the largest study of its kind

A large-scale study analyzed degenerative mitral valve disease patterns and outcomes, representing the largest cohort of its kind to date. The study provides comprehensive epidemiological and clinical data on disease progression, intervention timing, and patient outcomes in degenerative mitral regurgitation.

Digest: This dataset establishes important benchmarks for risk stratification and optimal timing of surgical or transcatheter mitral valve interventions in degenerative disease.

TMVRSurgicalGuidelinesRead original
CVB
news·20 days ago·Cardiovascular Business

TAVR linked to key benefits for select heart patients with moderate aortic stenosis

Transcatheter aortic valve replacement (TAVR) demonstrated clinical benefits in selected patients with moderate aortic stenosis, expanding potential indications beyond current severe stenosis criteria. The findings suggest TAVR may benefit a broader patient population than currently approved.

Digest: This represents a potential paradigm shift in TAVR eligibility that could significantly expand the treatable patient population and market, though awaits definitive trial data and regulatory consideration.

TAVRTrialGuidelinesFDARead original
AHA Heart News
news·20 days ago·AHA Heart News

Deaths from heart valve disease rising among U.S. adults ages 65 and older

Valvular heart disease mortality among U.S. adults aged 65 and older increased nearly 5% from 2018 to 2023, reversing a two-decade decline. Death rates rose from 104 to 109 per 100,000, with highest impact among men, non-Hispanic white adults, adults 85 and older, and nonmetropolitan residents.

Digest: Rising VHD mortality despite advances in transcatheter therapies signals potential gaps in early detection and access to valve interventions in aging and rural populations, informing market opportunity and healthcare delivery strategies.

AHAMarketGuidelinesRead original
CVB
news·30 days ago·Cardiovascular Business

Is surgical backup still necessary during TAVR? Opinions are mixed as bailout risk decreases

Debate continues regarding the necessity of on-site surgical backup during transcatheter aortic valve replacement procedures as complication rates requiring emergency conversion have decreased. The discussion reflects evolving procedural safety profiles and institutional experience with TAVR across different risk categories.

Digest: Resolution of the surgical backup requirement could expand TAVR availability to non-surgical centers and reduce procedural costs, though implications for patient safety and regulatory standards remain contentious.

TAVRSurgicalGuidelinesMarketRead original
CVB
news·about 1 month ago·Cardiovascular Business

SCAI's position on TAVR changes evolved after member survey

The Society for Cardiovascular Angiography and Intervention (SCAI) modified its official position statement regarding TAVR following feedback obtained through a membership survey. The society's evolving stance reflects input from its interventional cardiology membership base regarding contemporary TAVR practice and indications.

Digest: Professional society position statements from SCAI influence clinical practice patterns, institutional protocols, and regulatory considerations for TAVR utilization across risk categories.

TAVRGuidelinesSCAIRead original
CVB
news·about 1 month ago·Cardiovascular Business

PCI before TAVR may still be safest strategy for some heart patients

A clinical strategy analysis suggests that performing percutaneous coronary intervention prior to transcatheter aortic valve replacement may remain the safest approach for select patients with concurrent coronary artery disease and aortic stenosis. The recommendation addresses ongoing debate about optimal timing and sequencing of coronary revascularization in TAVR candidates.

Digest: This guidance impacts preprocedural planning and patient selection for the growing TAVR population, particularly as indications expand to lower-risk patients who may have longer life expectancy and therefore greater concern about untreated coronary disease.

TAVRGuidelinesLow RiskRead original
Diagnostic & Interventional Cardiology
research·about 2 months ago·Diagnostic & Interventional Cardiology

NIH Awards Grant to Help Improve Mitral Valve Surgery Decisions

Mount Sinai researchers received a $3.6 million, four-year NIH grant to develop EVOLVE-MR, a project linking randomized trial data with Medicare records to extend mitral valve surgery evidence to real-world populations. The study will use machine learning and causal inference methods to determine whether clinical trial benefits persist in broader, more diverse patient groups over longer follow-up periods.

Digest: This research addresses the critical gap between clinical trial populations and real-world mitral regurgitation patients, potentially enabling more individualized surgical decision-making for the 13 million U.S. adults with valvular heart disease.

TrialSurgicalGuidelinesReimbursementRead original
CVB
research·2 months ago·Cardiovascular Business

TAVR timing: Waiting more than 6 months may hurt survival odds

Patients who wait longer than 6 months to undergo transcatheter aortic valve replacement after indication may experience worse survival outcomes. The study suggests timely TAVR referral and performance is associated with improved mortality rates compared to prolonged delays.

Digest: This finding reinforces the importance of streamlined TAVR referral pathways and may influence heart team decision-making regarding procedural timing and patient selection strategies.

TAVRGuidelinesRead original
CVB
regulatory·2 months ago·Cardiovascular Business

Medical societies, aging advocates share early reactions to new TAVR policies

Medical societies and aging advocacy groups have issued initial responses to new CMS coverage policies affecting transcatheter aortic valve replacement. The policy changes appear to modify reimbursement or coverage criteria for TAVR procedures.

Digest: CMS coverage determinations directly impact TAVR access, reimbursement dynamics, and patient selection strategies for structural heart programs nationwide.

TAVRReimbursementGuidelinesRead original
CVB
news·3 months ago·Cardiovascular Business

TAVR and PCI: When heart patients need both, does the order matter?

The article addresses the clinical question of optimal sequencing when patients require both transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). The content explores whether performing PCI before, during, or after TAVR affects procedural outcomes and patient safety.

Digest: Concomitant coronary artery disease is common in TAVR candidates, and determining the optimal revascularization strategy impacts procedural planning, resource allocation, and patient outcomes for interventional cardiologists.

TAVRGuidelinesRead original
CVB
news·4 months ago·Cardiovascular Business

Expert panel explores TAVR’s present and future

An expert panel discussion examined current state and future directions of transcatheter aortic valve replacement technology and clinical practice. The panel format suggests coverage of evolving TAVR techniques, patient selection, and emerging challenges in the field.

Digest: Panel discussions at this stage of TAVR adoption typically address unresolved clinical questions around patient selection, durability, and expansion into lower-risk populations that guide practice patterns.

TAVRGuidelinesRead original
CVB
regulatory·4 months ago·Cardiovascular Business

Medical societies take a stand as CMS nears final decision on TAVR proposal

Medical societies are publicly responding to a CMS proposal regarding TAVR coverage as the agency approaches its final decision. The societies' positions indicate stakeholder engagement on potential changes to reimbursement or coverage criteria for transcatheter aortic valve replacement.

Digest: CMS coverage decisions directly impact patient access to TAVR and procedural volumes at structural heart programs, particularly if eligibility criteria or site-of-service requirements change.

TAVRReimbursementGuidelinesRead original
CVB
news·4 months ago·Cardiovascular Business

How AI can help heart teams identify TAVR patients

An article discusses how artificial intelligence can assist heart teams in identifying appropriate patients for transcatheter aortic valve replacement. No specific AI platform, clinical data, or implementation details were provided in the available content.

Digest: AI-driven patient identification tools could improve TAVR referral patterns and reduce undertreatment of severe aortic stenosis, though clinical validation and implementation strategies remain unclear from this report.

TAVRImagingGuidelinesRead original
CIRC
research·5 months ago·Circulation

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry

The American Heart Association published a report from the Target: AS Registry examining quality metrics for evaluation, surveillance, and management of aortic stenosis patients. The registry aims to establish benchmarks and identify gaps in AS care delivery across participating centers.

Digest: This AHA registry provides standardized quality measures that can guide institutional protocols for AS patient management and inform appropriate timing for intervention referrals.

AHAGuidelinesTAVRSAVRRead original
CVB
research·5 months ago·Cardiovascular Business

EARLY TAVR update: New data highlight continued benefits of treating asymptomatic aortic stenosis

New follow-up data from the EARLY TAVR trial demonstrate continued clinical benefits of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The updated results reinforce the safety and efficacy of early intervention before symptom onset in this patient population.

Digest: These findings support expanding TAVR utilization to asymptomatic patients with severe AS, potentially shifting treatment paradigms and increasing the addressable patient population for structural heart programs.

TAVRTrialGuidelinesRead original
CVB
research·5 months ago·Cardiovascular Business

Sex-specific outcomes after TAVR and SAVR: Key takeaways from a new meta-analysis

A new meta-analysis examined sex-specific outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR). The analysis revealed differential outcomes between male and female patients across the two treatment modalities.

Digest: Understanding sex-based differences in TAVR and SAVR outcomes can inform patient selection, procedural planning, and shared decision-making for aortic stenosis treatment.

TAVRSAVRGuidelinesRead original
CIRC
news·5 months ago·Circulation

A Slow Regular Rhythm After TAVR: A Clinical Reasoning Exercise

This clinical reasoning exercise presents a case of slow regular rhythm developing after transcatheter aortic valve replacement (TAVR). The article appears to be an educational case discussion focusing on the differential diagnosis and management of bradycardia post-TAVR.

Digest: Conduction abnormalities requiring pacemaker implantation remain a significant complication of TAVR, affecting clinical outcomes and resource utilization in structural heart programs.

TAVRGuidelinesRead original
Cardiovascular Business
research·5 months ago·Cardiovascular Business

Death after TAVR: New data support use of better patient assessments

A European registry of over 11,000 TAVR patients found that 4% died between 30 days and one year post-procedure despite uncomplicated courses, with 3.3% from non-cardiovascular causes. Independent predictors of delayed mortality included atrial fibrillation, COPD, severe chronic kidney disease, and reduced LVEF.

Digest: These findings emphasize the need for comprehensive multidisciplinary patient assessment beyond cardiac evaluation to identify patients at risk for futile TAVR interventions, particularly focusing on pulmonary and renal comorbidities that drive non-cardiovascular mortality.

TAVRHigh RiskGuidelinesRead original
CVB
news·5 months ago·Cardiovascular Business

TAVR concerns: Cardiologists, patient family members question quality of care at rural hospital

Cardiologists and patient family members have raised concerns about quality of care related to TAVR procedures at an unspecified rural hospital. Details regarding specific adverse events, procedural volumes, or outcomes data were not provided in the available content.

Digest: Quality concerns at low-volume rural TAVR centers may prompt scrutiny of procedural volume requirements and certification standards for transcatheter valve programs.

TAVRGuidelinesRead original
CVB
news·6 months ago·Cardiovascular Business

New guideline standardizes echo guidance for mitral transcatheter edge-to-edge repairs

A new guideline has been published to standardize echocardiographic guidance protocols for mitral transcatheter edge-to-edge repair (M-TEER) procedures. The guideline aims to harmonize imaging practices across operators and centers performing M-TEER interventions.

Digest: Standardized echo guidance protocols can improve procedural outcomes, reduce variability in M-TEER technique, and establish benchmarks for quality assurance in this growing mitral valve intervention field.

TMVRImagingGuidelinesRead original
CIRC
research·6 months ago·Circulation

Angiotensin Receptor Neprilysin Inhibitor in Heart Failure with Preserved Ejection Fraction and Secondary Mitral Regurgitation: the PRAISE-MR Randomized Trial

The PRAISE-MR randomized trial evaluated angiotensin receptor neprilysin inhibitor (ARNI) therapy in patients with heart failure with preserved ejection fraction (HFpEF) and secondary mitral regurgitation. The study assessed whether ARNI treatment could reduce mitral regurgitation severity and improve clinical outcomes in this patient population.

Digest: This trial addresses whether medical therapy with ARNI can reduce secondary MR in HFpEF patients, potentially identifying responders who may avoid transcatheter mitral intervention versus non-responders who require TMVR.

TrialTMVRGuidelinesRead original
CVB
news·6 months ago·Cardiovascular Business

Advocacy group wants TAVR changes, urging Trump admin to ‘stop getting in between patients and their doctors’

An advocacy group is calling on the Trump administration to change regulations or policies affecting transcatheter aortic valve replacement (TAVR) access, framing the issue as government interference in clinical decision-making. No specific policy changes, clinical data, or patient access barriers are detailed in the available content.

Digest: Potential regulatory or reimbursement policy changes could significantly impact TAVR utilization patterns and patient access, though the specific issues being advocated remain unclear from this brief report.

TAVRFDAReimbursementGuidelinesRead original
CVB
news·6 months ago·Cardiovascular Business

Is TAVR too common among younger patients? New data prompt a ‘call to action’

New data suggest transcatheter aortic valve replacement (TAVR) may be overutilized in younger, lower-risk patients, prompting experts to issue a call to action regarding patient selection. The findings raise concerns about long-term durability and outcomes in patients with longer life expectancy who may require reintervention.

Digest: This challenges current practice patterns in TAVR patient selection and has implications for guideline adherence, long-term valve durability considerations, and the appropriate balance between TAVR and SAVR in younger populations.

TAVRSAVRLow RiskDurabilityRead original
CVB
news·7 months ago·Cardiovascular Business

How expert guidelines have influenced TAVR vs. SAVR decisions

The article discusses how expert clinical practice guidelines have shaped decision-making between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). Specific data or findings are not provided in the submitted article content.

Digest: Guideline recommendations directly influence treatment algorithms and patient selection criteria, affecting procedural volumes, reimbursement patterns, and competitive positioning in the structural heart market.

TAVRSAVRGuidelinesACCRead original
CVB
news·7 months ago·Cardiovascular Business

TAVR or SAVR? Cardiologists and heart surgeons highlight the care that goes into each decision

Cardiologists and cardiac surgeons discuss the multidisciplinary approach and patient-specific factors involved in choosing between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). The article emphasizes individualized decision-making rather than presenting specific clinical data or trial outcomes.

Digest: Highlights the importance of heart team collaboration in TAVR versus SAVR selection, reinforcing guideline-recommended multidisciplinary evaluation as TAVR expands across risk cohorts.

TAVRSAVRGuidelinesRead original
AHA Heart News
news·7 months ago·AHA Heart News

Scientific researchers awarded $15 million to study heart valve disease

The American Heart Association awarded $15 million to three research centers (Mass General Brigham, Cincinnati Children's Hospital, and University of Pittsburgh) to establish a Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease. The four-year initiative addresses a growing global health burden affecting over 80 million people worldwide and contributing to more than 57,000 deaths annually in the U.S.

Digest: This dedicated funding network may accelerate discovery of biomarkers and diagnostic tools for pre-symptomatic valve disease detection, potentially expanding the treatable patient population before irreversible cardiac remodeling occurs.

AHAImagingGuidelinesMarketRead original
CVB
news·7 months ago·Cardiovascular Business

Early SAVR in asymptomatic heart patients linked to long-term benefits

Early surgical aortic valve replacement (SAVR) in asymptomatic patients with aortic stenosis demonstrated long-term clinical benefits compared to conservative management. The study suggests intervention prior to symptom onset may improve outcomes in select patients with severe AS.

Digest: This challenges the traditional watchful waiting approach for asymptomatic severe AS and may influence guideline recommendations regarding timing of intervention in this patient population.

SAVRTrialGuidelinesSurgicalRead original